- Home
- GNRC vs BIO Comparison
GNRC vs BIO Comparison
Compare GNRC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | BIO |
|---|---|---|
| Founded | 1959 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 8.2B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNRC | BIO |
|---|---|---|
| Price | $151.20 | $326.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 4 |
| Target Price | $188.72 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.2M | 176.1K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $4,352,444,000.00 | $2,557,500,000.00 |
| Revenue This Year | $2.33 | $1.89 |
| Revenue Next Year | $10.85 | $2.45 |
| P/E Ratio | $28.85 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $99.50 | $211.43 |
| 52 Week High | $203.25 | $373.69 |
Technical Indicators
Market Signals| Indicator | GNRC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 56.72 |
| Support Level | $143.61 | $298.35 |
| Resistance Level | $155.00 | $334.53 |
| Average True Range (ATR) | 6.76 | 11.27 |
| MACD | 0.67 | 1.34 |
| Stochastic Oscillator | 52.34 | 76.43 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.